Skip to content

All Sections

Tuesday, February 24th 2026

e-Edition

News
- News
- Crime and Public Safety
- Investigative Reporting
- Election
- Politics
- Health
- Environment
- Business
- Best Reviews
- Jobs
- Housing
- Weather
Local News
- Local News
- Pasadena
- San Marino
- Altadena
- San Gabriel
- Alhambra
- Monrovia
- Arcadia
- Temple City
- Monterey Park
- South Pasadena
- Duarte
- Rosemead
- Sierra Madre
- El Monte
- South El Monte
- Los Angeles
- Los Angeles County
Sports
- Sports
- LA Varsity
- Chargers
- Rams
- Lakers
- Clippers
- Dodgers
- Angels
- College Sports
- UCLA Sports
- USC Sports
- Kings
- Ducks
- Olympics
- Boxing/MMA
- Soccer
- Horse Racing
Things To Do
Obituaries
Opinion
SCNG Premium
Sponsored Content
Branded Content
- Paid Content by Brandpoint
The T.E.A.
Subscribe
Star-News Store
Log In
Logout

Get the latest news delivered daily!

Subscribe
Log In

Account Settings Contact Us Log Out

Spoof a user

Get the latest news delivered daily!

Subscribe
Log In

Pasadena Star News

Tuesday, February 24th 2026

e-Edition

News
Local News
Sports
Things to Do
Obituaries
Opinion
The T.E.A.

Trending:

Vote for Readers’ Choice 🗳
Weather news
Immigration news
Cardrooms anticipating layoffs
High school sports

Create Watchlist

Nasdaq Composite

San Gabriel Valley Index

San Gabriel Valley

Markets:

News

Aptevo Therapeutics Inc. - Common Stock (NQ:APVO)

6.712 +0.412 (+6.54%)

Streaming Delayed Price Updated: 3:36 PM EST, Feb 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Aptevo Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >

News headline image

Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth

February 03, 2026

Via ACCESS Newswire

News headline image

Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality

January 09, 2026

Via ACCESS Newswire

News headline image

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split

December 26, 2025

Via ACCESS Newswire

News headline image

Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025

December 09, 2025

Via ACCESS Newswire

News headline image

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

November 10, 2025

Via ACCESS Newswire

News headline image

Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

November 06, 2025

Via ACCESS Newswire

News headline image

Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter

October 08, 2025

Via ACCESS Newswire

News headline image

TOMI Environmental Solutions (NASDAQ: TOMZ): The Next Era of Disinfection Technology – More Stocks Inside

September 16, 2025

Via AB Newswire

News headline image

Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML

September 16, 2025

Via ACCESS Newswire

News headline image

Foremost Clean Energy and Aptevo Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

September 05, 2025

Via ACCESS Newswire

News headline image

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

September 04, 2025

Via ACCESS Newswire

News headline image

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

August 13, 2025

Via ACCESS Newswire

News headline image

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

August 11, 2025

Via ACCESS Newswire

News headline image

Aptevo Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

August 08, 2025

Via ACCESS Newswire

News headline image

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

June 20, 2025

Via ACCESS Newswire

News headline image

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

June 20, 2025

Via ACCESS Newswire

News headline image

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

June 18, 2025

Via ACCESS Newswire

News headline image

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

June 18, 2025

Via ACCESS Newswire

News headline image

Aptevo Participating in the BIO International Convention

June 13, 2025

Via ACCESS Newswire

News headline image

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

May 22, 2025

Via ACCESS Newswire

News headline image

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

May 14, 2025

Via ACCESS Newswire

News headline image

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

May 08, 2025

Via ACCESS Newswire

News headline image

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

April 22, 2025

Via ACCESS Newswire

News headline image

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

April 21, 2025

Via ACCESS Newswire

News headline image

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

April 04, 2025

Via ACCESS Newswire

News headline image

$2 Stocks to Watch: PNPN.V, TIVC, APVO, OSRH, PRSO Biotech Breakthroughs, MedTech Momentum Metallic Metals Power Play & Signal Innovation

April 03, 2025

Via AB Newswire

Topics Intellectual Property

News headline image

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

April 03, 2025

Via ACCESS Newswire

News headline image

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

March 20, 2025

Via ACCESS Newswire

News headline image

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

March 18, 2025

Via ACCESS Newswire

News headline image

Aptevo to Participate in March Conferences

March 06, 2025

Via ACCESS Newswire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

© 2025 FinancialContent. All rights reserved.

Subscribe
Advertising Solutions
About Pasadena Star News
Partners
Marketplace
Contact Us
Subscribe Now

Terms of Use
Cookie Policy
Cookie Preferences
California Notice at Collection
Notice of Financial Incentive
Do Not Sell/Share My Personal Information
Arbitration
Powered by WordPress.com VIP

Copyright 2026 Pasadena Star News. All rights reserved. The use of any content on this website for the purpose of training artificial intelligence systems, algorithms, machine learning models, text and data mining, or similar use is strictly prohibited without explicit written consent.